Overview of Rosuvas-F

Rosuvas-F is a synthetic prescription medication designed for the systemic management of elevated blood lipids, serving as a comprehensive Antihyperlipidemic Combination. It is formulated as an Oral Tablet and is specifically categorized as a Fixed-Dose Combination (FDC) product.

Property	Description
Active ingredient	Rosuvastatin and Fenofibrate
Form	Oral Tablet (Fixed-Dose Combination)
Pharmacological class	Antihyperlipidemic Combination (Statin and Fibrate)
Common use	Management of mixed dyslipidemia
Origin	Synthetic

What Type of Medicine is Rosuvas-F? (Classification and Form)

Rosuvas-F is a combination medicine belonging to two distinct and complementary pharmacological classes that address different aspects of fat metabolism. The first component, Rosuvastatin, is classified as an HMG-CoA Reductase Inhibitor (a statin), and the second component, Fenofibrate, is a Fibric Acid Derivative (a fibrate). This dual classification results from its two active ingredients, combined into a single dosage unit. The FDC structure simplifies the regimen for adults who require the combined therapeutic benefits of both a statin and a fibrate, a strategy that is clinically recognized for its efficiency in patients with multiple lipid goals.

Composition: Rosuvastatin and Fenofibrate (Active Ingredients)

The composition of Rosuvas-F centers on the two INN (International Nonproprietary Name) entities, Rosuvastatin and Fenofibrate, integrated with Solid Excipients necessary for the tablet form and Oral administration. Rosuvastatin is the agent primarily known for modifying cholesterol production, while Fenofibrate addresses the metabolism of triglycerides and other lipoproteins. The combination of statins and fibrates is a standard approach for managing lipid disorders requiring dual therapy. Using these two classes of medicine together addresses both high cholesterol and high triglycerides, and this Fixed-Dose Combination is often a preferred option when simplicity of administration is required, making it a key differentiator from taking two separate pills.

General Purpose and Dual-Action Approach (High-Level Benefit)

The general purpose of Rosuvas-F is to achieve comprehensive lipid control in patients diagnosed with conditions such as combined hyperlipidaemia or mixed dyslipidemia. It employs a dual-action approach where one component reduces the internal creation of cholesterol (cholesterol synthesis inhibition), and the other promotes the breakdown and clearance of circulating fats (lipid breakdown enhancement). A typical use scenario involves a patient where elevated lipid levels are characterized by both high levels of LDL cholesterol and high levels of triglycerides. This systemic action helps normalize lipid profiles by simultaneously managing both high cholesterol (hypercholesterolemia) and high triglycerides (hypertriglyceridemia).

Regulatory References

Fenofibrate: MedlinePlus Drug Information

What side effects are possible with Rosuvas-F?

Possible Side Effects and Safety Information

The safety profile of Rosuvas-F, a fixed-dose combination of Rosuvastatin and Fenofibrate, is determined by the documented adverse reactions of both component classes. The adverse reactions are classified by frequency as reported in regulatory documents.

Commonly Documented Adverse Reactions

Adverse reactions classified as common (occurring in at least 1 in 100 people) generally involve the nervous system, gastrointestinal system, and musculoskeletal system. These typically include headache, muscle pain (myalgia), nausea, abdominal pain, constipation, and asthenia (weakness). Increases in hepatic transaminases (liver enzymes) and the risk of new-onset Diabetes Mellitus are also officially listed as common.

Serious Adverse Reactions and Constraints

The most clinically significant concerns, listed as rare (occurring in less than 1 in 1,000 people), relate primarily to severe muscle toxicity and hepatic dysfunction. These include rhabdomyolysis (severe muscle breakdown that can lead to kidney damage), pancreatitis, and reports of hepatic failure. Hypersensitivity reactions, such as angioedema, are also documented as rare.

Regulatory documents impose specific safety constraints. The medication is officially contraindicated in individuals with active liver disease (including persistent, unexplained elevations of liver enzymes) and those with severe renal impairment. The risk of myopathy is specifically noted as being higher upon treatment initiation or dose escalation.

Overdose and Emergency Response

Rosuvas-F Overdose and When to Seek Help

Rosuvas-F is a combination medication containing Rosuvastatin and Fenofibrate. Taking more than the prescribed dose of this drug, either accidentally or intentionally, constitutes an overdose. While specific symptoms related to a combined overdose are not fully established, the effects are generally related to the pharmacological actions of the individual components.

Potential Overdose Symptoms

Component	Potential Symptoms of Overdose
Rosuvastatin	Rhabdomyolysis (muscle breakdown), acute kidney injury, liver toxicity
Fenofibrate	Liver enzyme elevation, muscle pain (myopathy)

In the event of an overdose, there is no specific antidote. Treatment is symptomatic and supportive, involving measures such as monitoring vital signs, managing any muscle-related symptoms, and providing general supportive care. Due to the high plasma protein binding of both components, dialysis is unlikely to be effective in removing the drug from the bloodstream.

When to Seek Immediate Help

If you suspect or confirm an overdose, contact emergency services or a poison control center immediately. Even if symptoms are not apparent, or if the amount taken is unknown, prompt professional medical evaluation is crucial. Do not induce vomiting unless instructed by medical personnel. Signs that require immediate attention include severe muscle pain or weakness, dark urine, or yellowing of the skin or eyes.

Therapeutic Uses of Rosuvas-F

What Rosuvas-F Treats: Main Uses and Benefits

Rosuvas-F is a combination lipid-lowering medication generally applied in the management of lipid imbalances in adults, relevant for supportive care in contexts involving long-term cardiovascular well-being. This combination is commonly used for conditions marked by both high cholesterol and high triglycerides.

Comprehensive Management of Mixed Dyslipidemia

The medication is generally used in conditions such as mixed dyslipidemia or combined hyperlipidaemia, where patients present with dual lipid abnormalities of high LDL cholesterol and highly elevated triglycerides. This therapy is generally applied in clinical settings where comprehensive management of both LDL-C and triglycerides is appropriate. The primary therapeutic benefit is to assist with balanced lipid profile management, which may help ease the overall systemic strain associated with abnormal blood fat markers.

Supportive Management of Cardiovascular Risk Factors

Rosuvas-F is typically prescribed as a component of a long-term strategy for managing cardiovascular risk factors. It is used to address the specific lipid markers of high LDL-C and high TG, which are known factors of cardiovascular risk. This approach contributes to the patient's overall cardiovascular well-being during chronic management and is especially relevant for patients with co-existing conditions such as Type 2 diabetes or metabolic syndrome.

Quick Fact: Relief for Lipid Imbalances
This combination supports the management of lipid markers in conditions where both LDL-C (bad cholesterol) and Triglycerides are significantly elevated, assisting in the broad management of abnormal fat profiles.

Eligibility and Restrictions for Use

The Rosuvastatin/Fenofibrate fixed-dose combination (Rosuvas-F) is officially restricted to adults who have been stabilized on the individual components. Regulatory documents outline strict conditions for eligibility and non-eligibility.

Contraindicated Populations (Must NOT Use)

Official labeling mandates that this medicine must not be used by patients with:

Active liver disease or persistent, unexplained elevations of liver enzymes.
Severe renal impairment (kidney disease).
Pre-existing gallbladder disease or Primary Biliary Cirrhosis.
A history of myopathy (muscle disorder).
Concomitant use with Ciclosporin.
Pregnancy or lactation; women of childbearing potential must use effective contraception.

Restricted or Conditional Use

Use of the FDC is not suitable for initial therapy for any patient population. It is also not recommended for patients with moderate hepatic impairment. Specific caution and dose initiation via monotherapy are required for:

Older adults (age 70 years and above).
Patients with moderate renal impairment.
Asian patients, due to higher systemic exposure to rosuvastatin.

What should I know about interactions with other medicines?

Rosuvas-F Interactions with other medicines and products

Category	Description
Interaction Scope	Medicinal product categories with documented interactions: Anticoagulants (Coumarin derivatives), Other Fibrates, Protease Inhibitors, Immunosuppressants, Antacids (Aluminum/Magnesium hydroxide combination), Lipid-modifying doses of Niacin, BCRP/OATP1B1 Inhibitors. Specific listed substances include Ciclosporin, Gemfibrozil, and certain anti-viral medicines like Sofosbuvir/Velpatasvir/Voxilaprevir.
Mechanistic basis of interactions	Interactions are officially documented to occur through two main mechanisms. The first is Inhibition of Drug Transporters (OATP1B1 and BCRP), leading to documented increased plasma concentration (PK Interaction). The second is an Additive Pharmacodynamic Effect, resulting in an elevated risk of myopathy or amplification of anticoagulant effects, such as INR prolongation with Coumarin Anticoagulants.
Timing-based interaction rules	Co-administration with Aluminum and Magnesium Hydroxide Combination Antacids requires separation; the medicine must be administered at least 2 hours after the antacid to mitigate a reduction in its systemic exposure.
Interaction-related restrictions	Co-administration is formally contraindicated or dose-restricted with substances such as Ciclosporin and specific Protease Inhibitors due to significant exposure modification. Use with Gemfibrozil is generally avoided due to documented additive pharmacodynamic risk. Restrictions also apply to the co-use of Lipid-modifying doses of Niacin and certain supplements like Red Yeast Rice.
Population-specific interaction notes	Official documentation notes that patients of Asian Ancestry and those with Severe Renal Impairment have increased systemic exposure and heightened risk of muscle-related effects, leading to specific restrictions.

The documented interaction structure results in explicit prohibitions against co-administering the drug with certain antivirals and immunosuppressants, as well as procedural constraints for monitoring when taken with anticoagulants. This structure ensures that co-administration risks are formally managed through clear regulatory restrictions, based on official safety and exposure data.

Mechanism of Action

How Rosuvas-F Works: Mechanism of Action

Dual Targeting of Hepatic Lipid Metabolism

This drug's mechanism involves two distinct, coordinated actions that modulate lipid processing within the liver. The core action is the competitive inhibition of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A ( HMG-CoA) reductase for cholesterol synthesis and the activation of the nuclear receptor PPARalpha to enhance fatty acid breakdown. This dual intervention alters the steady-state concentrations of lipoproteins in the bloodstream.

Cascade Effects on Cholesterol and Triglyceride Pathways

Rosuvastatin's inhibition of cholesterol synthesis initiates a cascade that upregulates LDL receptors on liver cells, which results in increased clearance of LDL-Cholesterol ( LDL-C) from circulation. Fenofibrate's PPARalpha agonism enhances the breakdown of VLDL and triglyceride-rich particles, resulting in a reduction in circulating triglycerides ( TG) and an increase in HDL-Cholesterol ( HDL-C).

Resulting Physiological Adjustments

The mechanism, by influencing LDL production and TG breakdown, alters the composition of the circulating lipoprotein pool. This coordinated activity modifies the concentrations of multiple circulating lipoproteins and influences the systemic lipid transport system.

Dosage and Administration Information

How Rosuvas-F is Used: Official Administration Principles

Rosuvas-F is an oral tablet used for the systemic, long-term management of elevated blood lipids, and its administration follows a standardized regimen based on its components, Rosuvastatin and Fenofibrate. As a Fixed-Dose Combination (FDC) product, it is generally not authorized for initial therapy; the appropriate doses of the individual components must be established first before switching to the FDC.

Administration Route and Timing

The medication is administered exclusively by the oral route, taken as a single dose once daily. The tablet can be taken at any time of day to maintain consistent systemic exposure. The tablet can be taken with or without food, offering flexibility for the user. For proper administration, the tablet must be swallowed whole and should not be crushed or chewed.

Standard Dosage and Population-Specific Rules

Treatment with Rosuvas-F is typically a long-term commitment. For the Rosuvastatin component, the usual adult dosage range is 5 mg to 40 mg once daily. Following initiation, the dosage is subject to titration (adjustment) based on the patient's lipid profile response, which is typically analyzed after a period of 2 to 4 weeks.

High-level adjustments are required for specific populations. For patients with severe renal impairment (non-dialysis), the dose of the Rosuvastatin component is limited and should not exceed 10 mg once daily. Additionally, a lower starting dose of 5 mg for the Rosuvastatin component is generally considered for Asian patients due to observed pharmacokinetic differences.

In the event a dose is missed, the standard procedure is to skip the missed dose and resume the schedule with the next dose at the regular time, rather than doubling the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Rosuvas-F

Mixed Hyperlipidemia (Combined High Cholesterol and Triglycerides)

Studies on the fixed combination of rosuvastatin and fenofibrate, which is the makeup of Rosuvas-F, have generally focused on people who have mixed hyperlipidemia, meaning they have high levels of both "bad" cholesterol (known as LDL-C) and high levels of blood fats called triglycerides. These are typically short-term, randomized, open-label, or observational studies, where researchers compare the combination treatment against taking rosuvastatin alone.

Research has examined whether the combination treatment affects markers beyond just cholesterol levels. While taking rosuvastatin by itself is very effective at lowering LDL-C, studies have compared the combination against rosuvastatin alone and reported that the combination was associated with a greater reduction in triglycerides and a greater increase in "good" cholesterol (known as HDL-C). The combination's use in individuals needing to target all three lipid components has been explored in research.

However, the evidence mainly revolves around how this combination changes blood test numbers (lipid profile) over a relatively short period, often around 30 days to a few months. It is not completely certain from the current research if these short-term improvements in blood markers translate into a long-term reduced risk of serious events like heart attacks and strokes compared to rosuvastatin monotherapy. More large-scale, long-term studies are needed to understand the full impact on overall heart health outcomes.

Use in Patients with Type 2 Diabetes

Some hospital-based, record-based, or observational studies have specifically investigated the combination's use in adults who have both Type 2 diabetes and dyslipidemia (abnormal blood fat levels). These studies, which look at patient data before and after treatment, have examined the combination's use for managing the complex lipid problems often seen in people with diabetes.

The findings from these specific populations reported that the combination was associated with changes in triglycerides and other related blood fat ratios, such as the ratio of triglycerides to HDL-C, after a few months of treatment. This is relevant because uncontrolled lipids in diabetes can significantly contribute to heart disease risk.

Similar to the general population studies, the research on diabetic patients is mostly limited to observations of changes in blood test results over a limited timeframe. There is not extensive long-term, large-scale evidence focusing on whether this combination leads to better prevention of major heart events in this specific group compared to other treatment approaches. Further long-term studies that specifically track heart health outcomes are necessary to draw firmer conclusions.

Special Populations and Research Gaps

Current research has paid some attention to the combination's use in patients with Type 2 diabetes, as mentioned above. Some studies have noted a possible difference in reported side effects, such as pain, nausea, and fatigue, between men and women using the combination. However, data on other special groups, such as children, the elderly, or those with varying degrees of kidney or liver conditions, are limited or focus more on the individual components rather than the specific combination product.

A key research gap is the scarcity of large, randomized clinical trials that track thousands of patients over several years. Most available evidence comes from smaller, shorter-term trials or from observational studies. While these studies evaluated the combination's ability to modify blood fat levels, the current research does not offer complete certainty about the long-term benefit of the combination over single-drug therapy in preventing heart attacks or strokes for the general population with mixed hyperlipidemia.

Key Studies & References

Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA's adverse event reporting system database

Frequently Asked Questions (FAQ)

Common questions about Rosuvas-F (FAQ)

Q: What kind of diet and lifestyle changes are recommended while taking Rosuvas-F?

Official product information indicates that Rosuvas-F is prescribed as an adjunct to diet. This means the treatment works in addition to a recommended low-saturated fat and low-cholesterol diet, along with other positive lifestyle adjustments. Regulatory documents describe the medication as a complement to these basic strategies for managing elevated lipids.

Q: Are there any known drug-food interactions with Rosuvas-F, like grapefruit?

Regulatory guidance states the tablet can be taken with or without food. However, rosuvastatin, one component of this medicine, has been associated with a potential increase in its systemic exposure (concentration in the bloodstream) when consumed with large amounts of grapefruit juice. Information regarding consumption of grapefruit should be reviewed by a healthcare professional.

Q: Can I consume alcohol in moderation while using Rosuvas-F?

Official product information notes that substantial quantities of alcohol should be avoided. Heavy alcohol use is associated with an increased risk of liver damage and may also elevate triglyceride levels, which could counteract the medication's intended benefits. The liver is a major focus of concern, as both components are processed through this organ.

Q: Can Rosuvas-F cause dizziness or affect a person's ability to drive?

Dizziness has been reported as a common side effect of the rosuvastatin component of this medicine. Official documents note that caution may be necessary when driving or operating machinery. This caution is advised until a patient understands how the medication affects their ability to perform these tasks safely.

Q: Is it true that Rosuvas-F can interact with certain antibiotics, like fusidic acid?

Regulatory documents strictly indicate that rosuvastatin (a component of Rosuvas-F) must not be co-administered with systemic formulations of the antibiotic fusidic acid. If treatment with fusidic acid is deemed essential, the statin therapy should be temporarily discontinued during the course of the antibiotic treatment. Regulatory documents indicate that co-administration may increase the risk of muscle-related effects.

Q: Can Rosuvas-F affect the effectiveness of oral contraceptives or HRT?

Official product information indicates that the rosuvastatin component may increase the exposure (concentration in the bloodstream) of certain hormonal contraceptives. Women who are using oral contraceptives or Hormone Replacement Therapy (HRT) should have this reviewed by a healthcare provider. This is noted as a necessary precaution for women of childbearing potential, who must use effective contraception during use.

Q: Does Rosuvas-F cause weight gain?

Official product information does not consistently list weight gain as a common or rare adverse event for the components of Rosuvas-F. While some adverse events, such as fatigue or the risk of new-onset diabetes mellitus, may be associated with metabolic changes, official data does not establish weight gain as a frequent side effect.

Q: Has Rosuvas-F been studied for use in children or adolescents?

According to official regulatory documents, the fixed-dose combination (FDC) formulation of Rosuvas-F is generally restricted to use in adults. The safety and effectiveness of this specific combined product have not been established for patients in children or adolescent age groups.

Q: Can a patient temporarily stop Rosuvas-F if they are having surgery?

Official warnings indicate that statin therapy may need to be temporarily discontinued in patients facing serious acute conditions, such as major surgery. This measure is typically taken because these conditions can predispose patients to a severe muscle condition known as rhabdomyolysis. Information regarding planned major surgery should be communicated to the prescribing physician.

Q: Can Rosuvas-F affect a person's joint health or cause joint pain?

Joint pain (formally known as arthralgia) has been documented in official product information as an adverse reaction associated with both active components of Rosuvas-F. Any persistent or severe joint discomfort should be reviewed by a healthcare provider.

Q: Does Rosuvas-F interact with common blood pressure medications?

Regulatory product information does not list common categories of blood pressure medications as having a specific contraindicated or dose-restricted interaction with Rosuvas-F. However, the official guidance emphasizes that all concomitant medicines should be reviewed by a physician.

Q: Is there any evidence about Rosuvas-F affecting memory or causing confusion?

Reports of memory loss and confusion have been associated with statin use in official post-marketing experience. These cognitive effects are generally reported as infrequent and non-serious. Any persistent or concerning cognitive issues should be discussed with a healthcare provider.

Q: Is it necessary to avoid certain types of fatty foods while taking this medicine?

The official labeling indicates that this medicine is used as an adjunct to a proper diet, which typically means a low-fat or low-cholesterol regimen. The aim is to use the medication alongside diet to help achieve comprehensive lipid control. Appropriate dietary restrictions should be discussed with a healthcare provider.

Q: Are there any known hematological effects, like changes to blood cell counts, from Rosuvas-F?

Changes in blood cell counts (hematological effects) have been identified in official post-approval data. Decreases in hemoglobin, hematocrit, and white blood cell counts have been documented during the use of the fenofibrate component. Such changes may be subject to monitoring during treatment.

How should Rosuvas-F be stored and disposed of?

Storage and Disposal Requirements

The storage and disposal instructions for Rosuvas-F tablets are derived from official regulatory labeling to maintain product quality and safety.

️ Storage Conditions

Requirement	Official Rule
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep the tablets protected from moisture, excess heat, and direct light.
Container	Must be kept in the original container and maintained tightly closed in a dry place.

️ Safety and Disposal

The medicine must be kept out of the sight and reach of children at all times.

Unused or expired Rosuvas-F must be safely disposed of according to local guidelines. If no official take-back program is available, the product should be mixed with an undesirable substance and placed in a sealed container before discarding in the household trash, in accordance with drug disposal procedures.

Rosuvas-F